Create Account | Sign In: Author or Forum

 
News  |  Journals  |  Conferences  |  Opinion  |  Articles  |  Forums  |  Twitter    
 
Category: Family Medicine | Geriatrics | Internal Medicine | Oncology | Urology | Journal

Back to Journal Articles

PSA Test Has Cut Metastatic Prostate Cancer at Presentation

Last Updated: July 30, 2012.

 

Based on pre-PSA testing era estimates, expected cases at presentation three-fold higher than observed

Share |

Comments: (0)

Tell-a-Friend

 

  Related
 
If incidence rates for the pre-prostate-specific antigen testing era (1983 to 1985) were present in the modern U.S. population, three times the number of men would have been expected to present with metastatic prostate cancer than the actual number observed in 2008, according to a study published online July 30 in Cancer.

MONDAY, July 30 (HealthDay News) -- If incidence rates for the pre-prostate-specific antigen (PSA) testing era (1983 to 1985) were present in the modern U.S. population, three times the number of men would have been expected to present with metastatic (M1) prostate cancer (PC) than the actual number observed in 2008, according to a study published online July 30 in Cancer.

Emil Scosyrev, Ph.D., from the University of Rochester Medical Center in New York, and colleagues estimated the total number of patients who would be expected to present with M1 PC in the modern U.S. population in a given year if the annual incidence rates of M1 PC were the same as the rates before PSA testing. The total number of men who presented in 2008 in the Surveillance, Epidemiology, and End Results nine registries area was computed, and the number of cases expected to occur in the absence of PSA testing was estimated.

The researchers found that, in 2008, the observed and expected numbers presenting with M1 PC were 739 and 2,277, respectively, with a 3.1 expected-to-observed ratio. Application of this ratio to the total U.S population in 2008 would have resulted in approximately 25,000 men presenting with M1 PC, compared with the actual observed number of approximately 8,000 men.

"We believe that these estimates must be taken into consideration (bearing in mind the limitations of observational data) when public health policy-level recommendations are made regarding PSA screening," the authors conclude.

Abstract
Full Text (subscription or payment may be required)

Copyright © 2012 HealthDay. All rights reserved.


Previous: Women With Diabetes Report Low Sexual Satisfaction Next: Self-Efficacy Predicts Fibromyalgia Symptomatology

Reader comments on this article are listed below. Review our comments policy.


Submit your opinion:

Name:

Email:

Location:

URL:

Remember my personal information

Notify me of follow-up comments?

advertisement.gif (61x7 -- 0 bytes)
 

Are you a Doctor, Pharmacist, PA or a Nurse?

Join the Doctors Lounge online medical community

  • Editorial activities: Publish, peer review, edit online articles.

Doctors Lounge Membership Application

 
     

 advertisement.gif (61x7 -- 0 bytes)

 

 

Useful Sites
MediLexicon
  Tools & Services: Follow DoctorsLounge on Twitter Follow us on Twitter | RSS News | Newsletter | Contact us
Copyright © 2001-2014
Doctors Lounge.
All rights reserved.

Medical Reference:
Diseases | Symptoms
Drugs | Labs | Procedures
Software | Tutorials

Advertising
Links | Humor
Forum Archive
CME | Conferences

Privacy Statement
Terms & Conditions
Editorial Board
About us | Email

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.